Cannabis Cultivar Collection Across Canada and the International Markets

Segra Enters Agreement to Offer Allele’s Proven Cannabis Cultivar Collection Across Canada and the International Markets

VANCOUVER, (March 10, 2021) Segra International Corp. and Allele Genetics, a subsidiary of Catalyst BC, are pleased to announce they have entered into an exclusive agreement to distribute Allele’s collection of data-backed “Proven Cultivar” cannabis cultivars within the Canadian market and other legal international markets. Allele’s Proven Cultivars have been grown at both a commercial scale and for breeding and agronomic dataset development for over a decade by one of the most experienced operational teams in the industry, Catalyst BC, and its affiliates. Harnessing the strength of its proven Plant Tissue Culture technology, Segra will be releasing Allele cultivars on an ongoing basis as part of its Verified Clean Stock program.

Allele’s Proven Culticars have been carefully selected based on cannabinoid profile and yield, terpene profiles, and key characteristics such as maturation cycle time, high-density trichome area index (“TAI”), mold/mildew resistance and high bract-to-leaf ratios. The ongoing cultivar releases will represent abroad palate of terpene profiles yielding flavors and aromas ranging from citrus to berry and cake to gas–flavors the modern cannabis consumer desires. Amplifying Allele’s Proven Winners with the power of Segra’s tissue culture technologies will ensure consistently high-performing plants that are, as with all Segra tissue culture plants, Verified Clean Stock. Segra and Allele are confident that this offering will help producers turn better plants into better profits.

“Segra is thrilled to be partnering more closely with Allele and able to offer a portion of their data-backed collection, through tissue culture, to operators,” said Segra CEO Jamie Blundell. “Allele has developed an incredible portfolio of diverse, premium cannabis cultivars through tremendous industry expertise and experience. Partnering with top genetics consultants, like Allele Genetics, is central to Segra’s ability to continuously provide our clients with the cultivars of the future, and we are keen to showcase how top genetics, paired with the performance of tissue culture, will lead to operational optimization for Canadian LPs.”

“Today’s cannabis consumer desires potency, flavor, and aroma. Allele’s Proven Cultivars is a collective team effort to enhance and elevate the evolving consumer experience. We have spent the better part of a decade collecting critical agronomic data and consumer feedback necessary to drive cannabis cultivar identification, selection, collection, trialing, and optimization.” Said Eric Forington, Director of Plant Breeding and Genetics at Allele Genetics. Our primary goal is an emphasis on both consumer experience, through consistently high-quality, high-potency, flavor and aroma-forward flower, and LP success by allowing superior genetics to do the heavy agronomic lifting. We are incredibly excited to support the distribution of our Proven Cultivars in the Canadian and legal global import/export markets through Segra’s proprietary micropropagation process and look forward to partnering with Segra to provide true-to-type, commercially viable plantlets at scale.”

To learn more about this partnership and how Segra and Allele’s Tissue Culture plantlets can improve your output and reduce risk, please contact Segra at info@segra-intl.com.
 
About Allele:
 
Allele Genetics has been redefining the boundaries of high THC, high terpene cannabis breeding for over two decades and has consistently raised the bar for Top-Shelf cannabis genetics. Our breeding programs are focused on ultra-high cannabinoid content and selections from our award-winning genetics catalog consistently test over 30% THC. Allele Genetics combines over 20 years of traditional commercial cannabis breeding experience with the latest science and technology, including micro-propagation and molecular breeding tools, to enhance trait stability and provide genetic identification for our unique cannabis cultivars. Learn more about our team here.
 
About Segra:
 
Segra is an agriculture technology company offering plant tissue culture and DNA fingerprinting services to accelerate the advancement of the cannabis industry. The company’s proprietary technologies empower its clients to drive financial performance and mitigate risk while exploring the next frontier of optimized cultivation practices for the rapidly evolving cannabis consumer. Segra has developed industrial-scale laboratories to produce disease-free, robust, and DNA-fingerprinted cannabis plantlets for licensed producers globally. To support this vision, Segra has assembled a world-class team of specialists in the fields of agronomy, molecular genetics, plant tissue culture, and regulatory compliance. Learn more about Segra here.
 
For Further Information:
 
Carson Otto
 
Forward-Looking Information:
 
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks, uncertainties, and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The company is under no obligation and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by applicable law.
 

Additional Resources

Consulting Services For Cannabis, Hemp, Psilocybin, and Natural Medicine

Testimonials and Public Relations

Latest Articles

  • Cannabis HVAC Design: The Psychrometrics of Profit and Operational Scalability in 2026
    In 2026, the global cannabis market has moved into a “Pharma-Grade” era. As of 2026, the leading cultivators are no longer just managing “temperature and humidity.” They are managing Vapor Pressure Deficit (VPD) and Biogenic Volatile Organic Compounds (BVOCs) to maximize secondary metabolite production (terpenes and cannabinoids) while slashing carbon footprints.
  • The 2026 Strategic Play: Mastering the New York Adult-Use Processor Type 3 Branding License
    In 2021, New York legalized. In 2025, it launched. In April 2026, the market is maturing at an unprecedented rate. The “green rush” of speculative applications has been replaced by a sophisticated “Branding Phase.” As of this month, the Office of Cannabis Management (OCM) has authorized over 532 processors, many of whom are actively seeking high-quality brand partners to fill their white-label capacity.
  • Don’t Get Left Behind: Securing Your New York Cannabis License in 2026
    The era of “provisional waiting” is over. The Office of Cannabis Management (OCM) has now issued over 2,160 adult-use licenses statewide. For entrepreneurs, the message is clear: the market is live, the supply chain is scaling, and the opportunity for professional, compliant operators has never been greater.
  • Overcoming the Complexities of Minnesota Cannabis Licensing in 2026: Navigating the Scale-Up Phase
    In 2026, Minnesota’s cannabis market has transitioned from initial launch to a high-stakes scale-up phase. To succeed, applicants must move beyond basic requirements to demonstrate “pharma-grade” compliance, long-term financial stability, and total operational readiness. We have outlined the most critical hurdles currently facing 2026 applicants – from navigating the 65% social equity ownership audit to overcoming the statewide testing bottleneck.
  • Cannabis Consumption Lounges: Which States Permit On-Site Use in 2026?
    Across much of the U.S., legally consuming cannabis remains largely restricted to private residences – and even then, landlords or HOAs frequently ban it. While retail sales are now legal in the majority of the country, a growing number of jurisdictions are finally moving beyond the “buy-it-and-go” model, authorizing public venues where adults can consume their purchases on-site in a social, regulated setting.
  • Virginia Cannabis Licensing & Business Opportunities (Updated April 2026)
    As Virginia transitions from its current “possession-only” model toward a fully regulated retail market, the 2026–2027 biennium represents a once-in-a-generation window for market entry. Unlike the vertically integrated “medical-only” regimes of the past, Virginia’s upcoming framework focuses on decentralization, specifically architected to favor small Virginia-based operators over large multi-state corporations.

Explore Our Articles

cannabis applications Cannabis Bar Cannabis Business Optmization cannabis careers Cannabis Compliance Cannabis Consumption Cannabis Consumption Bar Cannabis Inventory Management Systems Cannabis Investors cannabis jobs Cannabis Legalization cannabis licensing Cannabis Lounge cannabis marketing Cannabis Operational Procedures cannabis outreach Cannabis Regulations Cannabis Security Cannabis Software Cannabis Startup Cannabis Supply Chain Cannabis Technology Colorado controlled environment agriculture Cultivation cultivation facility Dispensary Design facility design Financial Planning HVAC HVACD Iowa Kansas Legal Update Legislation Medical Cannabis Minnesota Natural Medicine Nebraska New York Odor Control Oregon Psilocybin Psychedelics Recreational Cannabis

Scroll to Top